These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
345 related items for PubMed ID: 33084216
1. Alternative volumetric PET pjmirometers for evaluation of breast cancer cases with 18F-FDG PET/CT imaging: Metabolic tumour volume and total lesion glycolysis. Arslan E, Can Trabulus D, Mermut Ö, Şavlı TC, Çermik TF. J Med Imaging Radiat Oncol; 2021 Feb; 65(1):38-45. PubMed ID: 33084216 [Abstract] [Full Text] [Related]
2. The correlation of 18F-FDG PET/CT metabolic parameters, clinicopathological factors, and prognosis in breast cancer. Qu YH, Long N, Ran C, Sun J. Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540 [Abstract] [Full Text] [Related]
3. Prognostic value of metabolic tumour volume and total lesion glycolysis in 18F-FDG PET/CT scans in locally advanced breast cancer staging. Jiménez-Ballvé A, García García-Esquinas M, Salsidua-Arroyo O, Serrano-Palacio A, García-Sáenz JA, Ortega Candil A, Fuentes Ferrer ME, Rodríguez Rey C, Román-Santamaría JM, Moreno F, Carreras-Delgado JL. Rev Esp Med Nucl Imagen Mol; 2016 Mar; 35(6):365-372. PubMed ID: 26948652 [Abstract] [Full Text] [Related]
4. Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer. Sun M, Lu D, Li X, Wang J, Zhang L, Yang P, Yang Y, Shen J. Cancer Med; 2024 Sep; 13(18):e70216. PubMed ID: 39302034 [Abstract] [Full Text] [Related]
5. Metabolic parameters of [18F]FDG PET-CT before and after radiotherapy may predict survival and recurrence in cervical cancer. Markus M, Sartor H, Bjurberg M, Trägårdh E. Acta Oncol; 2023 Feb; 62(2):180-188. PubMed ID: 36815676 [Abstract] [Full Text] [Related]
6. [The relationship between (18)F-FDG PET/CT metabolic parameters and clinicopathological features of breast cancer]. Tang B, Zhang Y, Zhou J, Xu Y, Li TR, Ding CY. Zhonghua Zhong Liu Za Zhi; 2017 Apr 23; 39(4):280-285. PubMed ID: 28550668 [Abstract] [Full Text] [Related]
7. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents. Hwang SH, Cho A, Yun M, Choi YD, Rha SY, Kang WJ. Clin Nucl Med; 2017 May 23; 42(5):e235-e241. PubMed ID: 28288043 [Abstract] [Full Text] [Related]
8. Prognostic significance of metabolic tumor volume and total lesion glycolysis in patients with advanced cervical carcinoma. Calles-Sastre L, Mucientes-Rasilla J, San-Frutos Llorente LM, Royuela A, Garcia-Espantaleón Navas M, Herrero Gámiz S, Pérez-Medina T. Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019 May 23; 38(1):17-21. PubMed ID: 30366731 [Abstract] [Full Text] [Related]
9. Whole-Body Metabolic Tumor Volume, as Determined by (18)F-FDG PET/CT, as a Prognostic Factor of Outcome for Patients With Breast Cancer Who Have Distant Metastasis. Son SH, Lee SW, Jeong SY, Song BI, Chae YS, Ahn BC, Lee J. AJR Am J Roentgenol; 2015 Oct 23; 205(4):878-85. PubMed ID: 26204115 [Abstract] [Full Text] [Related]
17. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. Vargas HA, Burger IA, Goldman DA, Miccò M, Sosa RE, Weber W, Chi DS, Hricak H, Sala E. Eur Radiol; 2015 Nov 23; 25(11):3348-53. PubMed ID: 25916387 [Abstract] [Full Text] [Related]